Analysts Issue Forecasts for Exact Sciences Q1 Earnings

Exact Sciences Corporation (NASDAQ:EXAS) – Leerink Partnrs lowered their Q1 2026 earnings per share (EPS) estimates for Exact Sciences in a research note issued on Tuesday, November 4th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $0.09 per share for the quarter, down from their prior forecast of $0.17. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2026 earnings at $0.33 EPS, Q4 2026 earnings at $0.50 EPS and FY2027 earnings at $2.33 EPS.

Several other brokerages have also commented on EXAS. UBS Group decreased their price objective on Exact Sciences from $61.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, August 7th. Robert W. Baird increased their price objective on Exact Sciences from $72.00 to $88.00 and gave the company an “outperform” rating in a report on Tuesday. Benchmark increased their price objective on Exact Sciences from $60.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday. Guggenheim increased their price objective on Exact Sciences from $70.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wall Street Zen upgraded Exact Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $72.90.

Exact Sciences Stock Up 3.9%

Exact Sciences stock opened at $69.59 on Wednesday. The business has a fifty day moving average of $56.85 and a two-hundred day moving average of $53.02. The company has a quick ratio of 2.56, a current ratio of 2.89 and a debt-to-equity ratio of 0.94. The firm has a market cap of $13.17 billion, a P/E ratio of -12.82, a P/E/G ratio of 5.56 and a beta of 1.24. Exact Sciences has a twelve month low of $38.81 and a twelve month high of $72.83.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. The company had revenue of $850.74 million during the quarter, compared to analyst estimates of $810.42 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.Exact Sciences’s revenue was up 20.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.21) earnings per share. Exact Sciences has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Exact Sciences

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in Exact Sciences by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 17,637,674 shares of the medical research company’s stock worth $763,535,000 after purchasing an additional 617,384 shares during the period. Price T Rowe Associates Inc. MD grew its position in Exact Sciences by 11.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,403,872 shares of the medical research company’s stock worth $277,225,000 after purchasing an additional 643,631 shares during the period. Massachusetts Financial Services Co. MA grew its position in Exact Sciences by 31.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,909,501 shares of the medical research company’s stock worth $213,889,000 after purchasing an additional 939,888 shares during the period. Mackenzie Financial Corp grew its position in Exact Sciences by 12.4% during the 1st quarter. Mackenzie Financial Corp now owns 3,281,639 shares of the medical research company’s stock worth $142,062,000 after purchasing an additional 362,314 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Exact Sciences by 120.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,128,958 shares of the medical research company’s stock worth $135,453,000 after purchasing an additional 1,707,287 shares during the period. 88.82% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director James Edward Doyle sold 2,000 shares of the company’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the transaction, the director directly owned 57,962 shares of the company’s stock, valued at $3,477,720. This represents a 3.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.20% of the stock is currently owned by insiders.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.